PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
15.50%
Positive EBIT growth while AGEN is negative. John Neff might see a substantial edge in operational management.
16.24%
Positive operating income growth while AGEN is negative. John Neff might view this as a competitive edge in operations.
12.65%
Positive net income growth while AGEN is negative. John Neff might see a big relative performance advantage.
12.55%
Positive EPS growth while AGEN is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
12.55%
Positive diluted EPS growth while AGEN is negative. John Neff might view this as a strong relative advantage in controlling dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-72.30%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-72.30%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-364.91%
Negative 10Y OCF/share CAGR while AGEN stands at 55.01%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-364.91%
Negative 5Y OCF/share CAGR while AGEN is at 84.49%. Joel Greenblatt would question the firm’s operational model or cost structure.
-364.91%
Negative 3Y OCF/share CAGR while AGEN stands at 67.32%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-5621.33%
Negative 10Y net income/share CAGR while AGEN is at 48.97%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-5621.33%
Negative 5Y net income/share CAGR while AGEN is 75.49%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-5621.33%
Negative 3Y CAGR while AGEN is 48.82%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-1604.85%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-1604.85%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-1604.85%
Negative 3Y equity/share growth while AGEN is at 51.05%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-43.54%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-8.62%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
6.57%
Debt growth far above AGEN's 0.61%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-21.27%
We cut SG&A while AGEN invests at 41.44%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.